ACROBiosystems is going full steam ahead on developing a collection of recombinant antigens for these emerging variants. The reagents can rapidly assess the efficacy of existing therapeutics and vaccines against the variants and enable the development of mutation-resistant antibodies and vaccine candidates/booster shots.